Physician profile
Izzat E Carouba
NPI 1164517769
$9,921.60
in general payments reported to CMS, 2019-2025
49 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $1,330 · 2021: $2,185 · 2022: $1,484 · 2023: $1,238 · 2024: $1,237 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,193.28 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,015.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $979.91 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $757.40 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $736.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $556.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $529.42 | 2019-2024 | Ajovy, Austedo Xr |
| Abbvie INC. | $516.27 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $500.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $385.85 | 2019-2023 | |
| Dexcom, INC. | $354.61 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $341.38 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $232.20 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $189.42 | 2020-2021 | |
| Ucb, INC. | $140.84 | 2020-2023 | Nayzilam |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $120.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.37 | 2019-2022 | |
| Astellas Pharma US INC | $95.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $94.64 | 2023-2024 | Verquvo, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.88 | 2019-2024 | Xifaxan |
| Lundbeck LLC | $88.53 | 2024-2025 | Rexulti |
| Abbott Laboratories | $86.00 | 2022-2025 | Freestyle Libre 3 |
| Biogen, INC. | $70.92 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $61.83 | 2019-2023 | Nuplazid |
| Inspire Medical Systems, INC. | $61.67 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $48.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.19 | 2020-2021 | |
| Exact Sciences Corporation | $41.95 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.88 | 2020-2021 | |
| Insmed, INC. | $36.28 | 2021-2022 | |
| Abiomed | $36.27 | 2023-2024 | Impella |
| Ethicon INC. | $34.02 | 2025 | Monarch Platform |
| Ironwood Pharmaceuticals, INC | $33.81 | 2019-2020 | |
| Depuy Synthes Sales INC. | $30.04 | 2025 | Foot Osteotomy Wedge System |
| Allergan, INC. | $29.37 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $22.45 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $20.52 | 2024 | Auvelity |
| Ani Pharmaceuticals, INC. | $20.46 | 2024 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $20.21 | 2025 | General - Pain Management |
| Takeda Pharmaceuticals U.S.A., INC. | $19.45 | 2024 | Vpriv |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.25 | 2022 | |
| Kaleo, INC. | $18.49 | 2022 | |
| Inari Medical, INC. | $18.46 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Electromed, INC. | $18.12 | 2022 | |
| Lucid Diagnostics INC. | $17.45 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $15.86 | 2024 | Rhythm Express |
| Circassia INC. | $14.79 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.21 | 2024 | Onpattro |
| Daiichi Sankyo INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Izzat Carouba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.